Rani Therapeutics Holdings, Inc. financial data

Symbol
RANI on Nasdaq
Location
San Jose, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 80% % -70%
Debt-to-equity -764% % -236%
Return On Equity 493% %
Return On Assets -129% % -127%
Operating Margin -3728% %

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $51,900,000 USD -4.1%
Weighted Average Number of Shares Outstanding, Basic 46,444,000 shares 61%
Weighted Average Number of Shares Outstanding, Diluted 46,444,000 shares 61%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $1,200,000 USD
Research and Development Expense $22,105,000 USD -20%
General and Administrative Expense $20,113,000 USD -17%
Operating Income (Loss) $44,732,000 USD 14%
Net Income (Loss) Attributable to Parent $28,315,000 USD -0.52%
Earnings Per Share, Basic 0 USD/shares 26%
Earnings Per Share, Diluted 0 USD/shares 26%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,144,000 USD -3.1%
Accounts Receivable, after Allowance for Credit Loss, Current $600,000 USD
Assets, Current $4,955,000 USD -85%
Property, Plant and Equipment, Net $922,000 USD -83%
Operating Lease, Right-of-Use Asset $4,017,000 USD -26%
Other Assets, Noncurrent $245,000 USD -0.41%
Assets $10,139,000 USD -77%
Accounts Payable, Current $2,467,000 USD 58%
Liabilities, Current $19,144,000 USD -5.3%
Operating Lease, Liability, Noncurrent $2,968,000 USD -26%
Liabilities $22,112,000 USD -41%
Accumulated Other Comprehensive Income (Loss), Net of Tax $3,000 USD -62%
Retained Earnings (Accumulated Deficit) $122,275,000 USD -30%
Stockholders' Equity Attributable to Parent $7,860,000 USD -352%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $11,973,000 USD -307%
Liabilities and Equity $10,139,000 USD -77%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,149,000 USD 13%
Net Cash Provided by (Used in) Financing Activities $3,731,000 USD -3183%
Net Cash Provided by (Used in) Investing Activities $18,229,000 USD 77%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $6,349,000 USD 527%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,644,000 USD -2.8%
Deferred Tax Assets, Valuation Allowance $69,072,000 USD 13%
Deferred Tax Assets, Gross $69,072,000 USD 13%
Operating Lease, Liability $4,017,000 USD -26%
Payments to Acquire Property, Plant, and Equipment $51,000 USD 183%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $28,607,000 USD -1.7%
Lessee, Operating Lease, Liability, to be Paid $4,770,000 USD -28%
Operating Lease, Liability, Current $1,049,000 USD -26%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,229,000 USD -35%
Lessee, Operating Lease, Liability, to be Paid, Year One $475,000 USD 2.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $753,000 USD -39%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,278,000 USD 4%
Deferred Tax Assets, Operating Loss Carryforwards $19,384,000 USD 49%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20,000,000 shares 0%
Unrecognized Tax Benefits $661,000 USD 35%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,330,000 USD 4.1%
Operating Lease, Payments $473,000 USD 163%
Additional Paid in Capital $114,406,000 USD 18%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $3,925,000 USD 1.4%
Interest Expense $3,671,000 USD -29%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%